Advances in cellular immunotherapy have revolutionized cancer treatment, yet significant challenges such as high costs and limited antigen specificity persist, particularly in combating B lymphoma. A newly published study in the journal Engineering addresses these hurdles by elucidating cutting-edge techniques for live-cell glycocalyx engineering, offering a transformative approach to optimize adoptive cell therapies (ACTs). This groundbreaking research from Peking University and international collaborators contrasts metabolic glycocalyx engineering (MGE) with chemoenzymatic glycocalyx engineering (CeGE), focusing on how these methodologies modify the molecular architecture of immune effector cells to enhance their targeting efficiency and therapeutic potential.
The glycocalyx, a dense matrix of glycoproteins and glycolipids on cell surfaces, governs critical biological processes such as cell recognition, adhesion, and signaling. Modulating this extracellular layer represents a promising strategy to augment immune cell functions without permanently altering their genetic composition. MGE facilitates the incorporation of unnatural monosaccharide analogs into glycans through cellular metabolic pathways, enabling azide-labeled sialic acids to be displayed on the cell surface. In contrast, CeGE employs the enzymatic attachment of specific glycan ligands, directed by the transferase ST6Gal1, to remodel the glycocalyx with high precision and efficiency. By systematically evaluating these two techniques in NK-92MI natural killer cells, the team provides a detailed comparative mechanistic framework that highlights the strengths and limitations of each approach.
Their analyses reveal that CeGE offers comparable, and in some instances superior, ligand-loading efficiency relative to MGE, significantly influencing the composition of the NK-92MI glycocalyx. Notably, CeGE-mediated modifications were found to specifically target components of the immune synapse, which is instrumental in cell-cell communication and cytotoxic responses against tumor cells. This spatial reorganization of recognition molecules could potentiate NK cell-mediated cytotoxicity by enhancing the precision of target cell engagement. Glycoproteomic profiling further confirms that enzymatic remodeling can be fine-tuned to modify subsets of glycan epitopes, providing unprecedented control over the cellular glycome.
Expanding the utility of glycocalyx engineering, researchers successfully established orthogonal ligand platforms on NK-92MI cells by introducing α2,3-sialylated N-acetyllactosamine structures, thus generating selectin ligands that mediate homing to sites of inflammation or tumor microenvironments. These modifications markedly improved in vivo efficacy in murine models of B lymphoma xenografts, demonstrating enhanced trafficking and tumor cell elimination. By leveraging the adhesive properties of selectins, these engineered cells exhibit superior navigational and targeting capabilities, addressing a critical bottleneck in ACT applications where effective cellular homing is paramount.
The team also extended their approach to chimeric antigen receptor T (CAR-T) cells engineered to target the CD19 antigen, a primary marker exploited in B-cell malignancies. Through the incorporation of a chemically modified sialic acid derivative, 9-N-m-phenoxybenzamide–N-acetylneuraminic acid (MPB-Neu5Ac), the researchers achieved bitargeting of CD19 and CD22 antigens, expanding the scope and specificity of CAR-T mediated cytotoxicity. This dual-targeting strategy is pivotal in overcoming antigen escape variants and tumor relapse that often plague single antigen-targeted therapies. The modified CAR-T cells demonstrated enhanced tumor recognition and killing efficiency, providing a cost-effective and transgene-free method to boost therapeutic outcomes substantially.
Crucially, both MGE and CeGE approaches exhibited robust biocompatibility, preserving the viability and proliferative capacity of NK-92MI and CAR-T cells, which underscores their practicality for clinical translation. The non-genetic nature of these methods circumvents potential safety concerns associated with permanent genome editing, such as off-target effects and insertional mutagenesis, thereby presenting a safer alternative for engineering immune cells. This flexibility ensures that engineered glycan modifications can be dynamically tuned or reversed, adapting to patient-specific and temporal therapeutic needs.
The study pioneers a versatile platform to customize glycocalyx composition with high-avidity glycan ligands that selectively target key molecules like CD22 and selectins. This level of control can fundamentally transform adoptive cell therapies by enhancing immune cell targeting precision, improving in vivo persistence, and facilitating tumor infiltration. Such refinements are critical for advancing ACT approaches beyond current limitations imposed by antigen heterogeneity and immune evasion mechanisms inherent in hematologic malignancies.
By establishing a detailed mechanistic basis for glycocalyx remodeling, this research unravels new frontiers in carbohydrate chemistry and immunoengineering. It lays the groundwork for future explorations into multiplexed glycan modifications that may synergize with other therapeutic modalities, including checkpoint inhibitors and cytokine therapies, amplifying the immune system’s capacity to eradicate cancer. The findings represent a paradigm shift towards harnessing the dynamic, modifiable properties of the glycocalyx to equip immune cells with enhanced functionality without the complexities of genetic reprogramming.
Moreover, the implications of this work extend beyond B lymphoma to encompass a broad spectrum of cancers where tailored immune cell trafficking and antigen targeting could overcome prevailing therapeutic resistance. By integrating sophisticated chemoenzymatic tools with metabolic labeling strategies, researchers and clinicians gain a powerful arsenal to refine cellular immunotherapies with unprecedented specificity and efficacy. This versatile toolkit heralds a new era in personalized medicine, where the biochemical landscape of immune cells is sculpted with surgical precision.
In summary, this comprehensive comparative study spotlights live-cell glycocalyx engineering as a transformative, transgene-free modality to potentiate adoptive cell therapies targeting B lymphoma. The rational design principles and mechanistic insights provided herein accelerate the conceptual and translational journey towards next-generation immunotherapies with enhanced tumor selectivity, improved in vivo behaviors, and reduced relapse incidence. Such technological innovations promise to elevate the therapeutic index of cellular therapies, reduce costs, and broaden their applicability in oncology and beyond.
The paper titled “A Comparative Mechanistic Study of Live-Cell Glycocalyx Engineering: Improving Adoptive Cell Therapies Against B Lymphoma” is authored by Yuxin Li, Tao Gao, Zhaoxin Han, Valeria M. Stepanova, Han Wang, Hongmin Chen, Alexey Stepanov, and Senlian Hong. This open-access study was published on February 17, 2026, in the journal Engineering, and can be accessed at https://doi.org/10.1016/j.eng.2025.08.037. The work represents a landmark contribution to the evolving interface of glycobiology and cellular immunotherapy.
Subject of Research: Glycocalyx engineering in adoptive cell therapies for B lymphoma
Article Title: A Comparative Mechanistic Study of Live-Cell Glycocalyx Engineering: Improving Adoptive Cell Therapies Against B Lymphoma
News Publication Date: 17-Feb-2026
Web References: https://doi.org/10.1016/j.eng.2025.08.037, https://www.sciencedirect.com/journal/engineering
Image Credits: Yuxin Li, Tao Gao et al.
Keywords: Adoptive cell therapy, glycocalyx engineering, metabolic glycoengineering, chemoenzymatic glycoengineering, NK-92MI cells, CAR-T cells, B lymphoma, immune synapse, glycoproteomics, selectin ligands, CD19/CD22 targeting, cancer immunotherapy
